Randomised phase II evaluation of irinotecan plus high-dose 5-fluorouracil and leucovorin (ILF) vs 5-fluorouracil, leucovorin, and etoposide (ELF) in untreated metastatic gastric cancer.
作者： M Moehler , A Eimermacher , J Siebler , T Höhler , A Wein
关键词:
摘要: … was sufficiently manageable to allow outpatient-based treatment. Therefore, we initiated the present randomised, controlled, phase II study to compare the efficacy and safety of ILF with …
nature.com
sci-hub.se 参考文章(26)
A Wakui, T Taguchi, Y Sakata, M Yoshino, Y Shimada, K Futatsuki, I Nakao, N Ogawa, M Kambe, [Late phase II study of irinotecan hydrochloride (CPT-11) in advanced gastric cancer. CPT-11 Gastrointestinal Cancer Study Group]. Gan to kagaku ryoho. Cancer & chemotherapy. ,vol. 21, pp. 1033- 1038 ,(1994)
B. Rau, M. Hünerbein, B. Reingruber, P. Hohenberger, P. M. Schlag, Laparoscopic Lymph Node Assessment in Pretherapeutic Staging of Gastric and Esophageal Cancer Recent results in cancer research. ,vol. 142, pp. 209- 215 ,(1996) , 10.1007/978-3-642-80035-1_13
Robbert J. van Alphen, Alex Sparreboom, Kees Nooter, Ron H. J. Mathijssen, Walter J. Loos, Gerrit Stoter, Jaap Verweij, Clinical pharmacokinetics and metabolism of irinotecan (CPT-11) Clinical Cancer Research. ,vol. 7, pp. 2182- 2194 ,(2001)
Udo Vanhoefer, Philippe Rougier, Hansjochen Wilke, Michel P. Ducreux, Angel J. Lacave, Eric Van Cutsem, Manfred Planker, José Guimaraes Dos Santos, Pascal Piedbois, Bernard Paillot, Heinrich Bodenstein, Hans-Jochen Schmoll, Harry Bleiberg, Bernard Nordlinger, Marie-Laure Couvreur, Benoit Baron, Jacques A. Wils, Final Results of a Randomized Phase III Trial of Sequential High-Dose Methotrexate, Fluorouracil, and Doxorubicin Versus Etoposide, Leucovorin, and Fluorouracil Versus Infusional Fluorouracil and Cisplatin in Advanced Gastric Cancer: A Trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group Journal of Clinical Oncology. ,vol. 18, pp. 2648- 2657 ,(2000) , 10.1200/JCO.2000.18.14.2648
Andre M. Murad, Flavia F. Santiago, Andy Petroianu, Paulo R. S. Rocha, Marco A. G. Rodrigues, Marcelo Rausch, Modified therapy with 5‐fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer Cancer. ,vol. 72, pp. 37- 41 ,(1993) , 10.1002/1097-0142(19930701)72:1<37::AID-CNCR2820720109>3.0.CO;2-P
J S Waters, A Norman, D Cunningham, J H Scarffe, A Webb, P Harper, J K Joffe, M Mackean, J Mansi, M Leahy, A Hill, J Oates, S Rao, M Nicolson, T Hickish, Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial. British Journal of Cancer. ,vol. 80, pp. 269- 272 ,(1999) , 10.1038/SJ.BJC.6690350
S-H Lee, W K Kang, J Park, H Y Kim, J H Kim, S I Lee, J O Park, K Kim, C W Jung, Y S Park, Y-H Im, M H Lee, K Park, Combination chemotherapy with epirubicin, docetaxel and cisplatin (EDP) in metastatic or recurrent, unresectable gastric cancer. British Journal of Cancer. ,vol. 91, pp. 18- 22 ,(2004) , 10.1038/SJ.BJC.6601891
S Pyrhönen, T Kuitunen, P Nyandoto, M Kouri, Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. British Journal of Cancer. ,vol. 71, pp. 587- 591 ,(1995) , 10.1038/BJC.1995.114
Jochen Rudi, Henning Schulze-Bergkamen, Ivan Zuna, Andreas Teufel, Wolfgang Stremmel, Treatment of advanced gastric cancer with etoposide, folinic acid, and fluorouracil in the clinical setting: efficacy of therapy and value of serum tumor markers. Medical Oncology. ,vol. 19, pp. 43- 53 ,(2002) , 10.1385/MO:19:1:43
C-H Köhne, R Catane, B Klein, M Ducreux, P Thuss-Patience, N Niederle, M Gips, P Preusser, A Knuth, M Clemens, R Bugat, I Figer, A Shani, B Fages, D Di Betta, C Jacques, H J Wilke, Irinotecan is active in chemonaive patients with metastatic gastric cancer: a phase II multicentric trial British Journal of Cancer. ,vol. 89, pp. 997- 1001 ,(2003) , 10.1038/SJ.BJC.6601226